Biosimilars Access and Affordability Act
The source supplies the latest action, but no lifecycle stage.
Latest action (28 Sep 2026): Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
What this bill does
This bill, H.R. 10628, titled "To amend title XI of the Social Security Act to alter when biosimilar biological products are eligible for price negotiations under the Medicare program," was introduced by Representative Nicholas Langworthy. As its title indicates, the bill proposes changes to the rules surrounding when biosimilar biological products can be included in price negotiations for the Medicare program.
The bill would specifically affect the eligibility of biosimilar biological products for Medicare price negotiations. It is not yet clear from the provided information precisely how this eligibility would be altered. The full text of the bill, which would detail the specific changes, has not yet been published.
H.R. 10628 is currently in the initial stage of the legislative process, having been introduced in the 119th Congress on September 28, 2026. Its current status is "Introduced." From here, the bill would typically move to committee review, where it could be debated, amended, and voted upon before potentially advancing to the full House of Representatives for consideration.
Plain-English summary generated by Bill100 AI from the official record. Always verify against the source below.
Timeline
28 Sep 2026
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Common questions
- What does H.R. 10628 do?
- This bill, H.R. 10628, titled "To amend title XI of the Social Security Act to alter when biosimilar biological products are eligible for price negotiations under the Medicare program," was introduced by Representative Nicholas Langworthy. As its title indicates, the bill proposes changes to the rules surrounding when biosimilar biological products can be included in price negotiations for the Medicare program. The bill would specifically affect the eligibility of biosimilar biological products for Medicare price negotiations. It is not yet clear from the provided information precisely how this eligibility would be altered. The full text of the bill, which would detail the specific changes, has not yet been published. H.R. 10628 is currently in the initial stage of the legislative process, having been introduced in the 119th Congress on September 28, 2026. Its current status is "Introduced." From here, the bill would typically move to committee review, where it could be debated, amended, and voted upon before potentially advancing to the full House of Representatives for consideration.
- Has H.R. 10628 become law?
- The source does not supply a confirmed lifecycle stage for H.R. 10628. Check the latest action and official source below.
- Who sponsored H.R. 10628?
- H.R. 10628 was sponsored by Rep. Langworthy, Nicholas A. [R-NY-23] (R-NY), with 11 cosponsors.
- What's the latest action on H.R. 10628?
- Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. (28 Sep 2026).
Related bills in Health
Choices for Increased Mobility Act of 2026
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
340B Rebate Model Delay Act
Lower Premiums, Faster Payments Act
More bills from Rep. Langworthy, Nicholas A. [R-NY-23]
Surge to Save Newborns Act
Companion Animal Protection Against Cruel Testing Act
FLOWS Act
CHECK Act of 2026
Bill100 mirrors the public U.S. legislative record from Congress.gov and GovTrack and adds plain-English AI summaries. It is an information tool, not legal, compliance or lobbying advice, and it is not affiliated with the U.S. Congress or any government agency. AI summaries can simplify or omit detail — every bill links to the official source; verify there before you rely on it.